Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer.

Cited by (760)

Items 101–200 of 760

1. PFKFB3 mediates tubular cell death in cisplatin nephrotoxicity by activating CDK4
   Lu Wen, Qingqing Wei, Man Jiang Livingston, Guie Dong, Siyao Li, Xiaoru Hu, Ying Li, Yuqing Huo, Zheng Dong · 2022 · Translational research
2. Real-world effectiveness of ribociclib in metastatic breast cancer patients: Does dose affect survival?
   Cristina Fernández-Cuerva, Teresa Chinchilla-Alarcón, Juan José Alcaraz-Sánchez · 2022 · Journal of Oncology Pharmacy Practice
3. Real-world treatment patterns of subsequent therapy after palbociclib in patients with advanced breast cancer in Japan
   Masataka Sawaki, Yasuaki Muramatsu, Kanae Togo, Hiroji Iwata · 2023 · The Breast
4. Clinical Impact of CDK4/6 Inhibitors in De Novo or PR− or Very Elderly Post-Menopausal ER+/HER2− Advanced Breast Cancers
   Hiu Tang, Daniel Yeo, Karen DeSouza, Omar Ahmad, Tahir Shafiq, Okezie Ofor, Anjana Anand, Syed Karim, Sarah N. Khan, Srinivasan Madhusudan · 2023 · Cancers
5. A network meta-analysis of efficacy and safety for first-line and second/further-line therapies in postmenopausal women with hormone receptor-positive, HER2-negative, advanced breast cancer
   Hanqiao Shao, Mingye Zhao, Ai‐Jia Guan, Taihang Shao, Dachuang Zhou, Guo Yu, Wenxi Tang · 2024 · BMC Medicine
6. CDK4/6 inhibitors: The Devil is in the Detail
   Tara Magge, Sneha Rajendran, Adam Brufsky, Julia Foldi · 2024 · Current Oncology Reports
7. Cost-effectiveness of CDK4/6 inhibitors in HR+/HER2− metastatic breast cancer: a systematic review and meta-analysis
   Prajakta P. Masurkar, Prachi Prajapati, Joanne Canedo, Swarnali Goswami, Sally R. Earl, Kaustuv Bhattacharya · 2024 · Current Medical Research and Opinion
8. Efficacy and Safety of CDK4/6 Inhibitors: A Focus on HR+/HER2− Early Breast Cancer
   Eva Valentina Klocker, Daniel Egle, Rupert Bartsch, Gabriel Rinnerthaler, Michael Gnant · 2025 · Drugs
9. Survival Following CDK4/6 Inhibitor Therapy for Hormone Receptor–Positive, ERBB2–Negative Metastatic Breast Cancer
   Pier Paolo Maria Berton Giachetti, Stefania Morganti, Sara Gandini, Fabiola Giudici, Antonio Marra, Eleonora Nicolò, Emma Zattarin, Chiara Corti, Laura Boldrini, Annarita Verrazzo et al. · 2025 · JAMA Network Open
10. Drug-Drug interactions and special considerations in breast cancer patients treated with CDK4/6 inhibitors: A comprehensive review
    Taha Koray Şahin, Gözde Kavgacı, Deniz Can Güven, Sercan Aksoy · 2025 · Cancer Treatment Reviews
11. Real-world progression-free survival of CDK4/6 inhibitors plus an aromatase inhibitor in HR-positive/HER2-negative metastatic breast cancer in United States routine clinical practice
    Hope S. Rugo, Rachel M. Layman, Filipa C. Lynce, Xianchen Liu, Benjamin C. Li, Lynn McRoy, Aaron Benjamin Cohen, Melissa Estévez, Giuseppe Curigliano, Adam Brufsky · 2025 · ESMO Open
12. Cyclin-dependent kinase 4/6 inhibitor-associated thromboembolism: a critical evaluation of the current evidence
    Nathan Watson, Joseph James Shatzel, Hanny T. Al-Samkari · 2023 · Journal of Thrombosis and Haemostasis
13. Targeting Inhibitor of Apoptosis Proteins to Overcome Chemotherapy Resistance—A Marriage between Targeted Therapy and Cytotoxic Chemotherapy
    Tiago Barroso, Cecília Melo-Alvim, Leonor Ribeiro, Sandra Casimiro, Luís Costa · 2023 · International Journal of Molecular Sciences
14. The trend toward more target therapy in pancreatic ductal adenocarcinoma
    Chiara Deiana, Margherita Agostini, Giovanni Brandi, Elisa Giovannetti · 2024 · Expert Review of Anticancer Therapy
15. Advances in Personalized Oncology
    Hiba Mechahougui, James Gutmans, Gina Colarusso, Roumaïssa Gouasmi, Alex Friedlaender · 2024 · Cancers
16. Therapeutic targeting of circTNK2 with nanoparticles restores tamoxifen sensitivity and enhances NK cell-mediated immunity in ER-positive breast cancer
    Runxin Wu, Shubin Yu, Aiwei Bi et al. · 2025 · Cancer Letters
17. Breast cancers arising in subjects with germline BRCA1 or BRCA2 mutations: Different biological and clinical entities with potentially diverse therapeutic opportunities
    Emma Zattarin, Ida Taglialatela, Riccardo Lobefaro, Rita Leporati, Giovanni Fucà, Francesca Ligorio, Caterina Sposetti, Leonardo Provenzano, Jacopo Azzollini, Andrea Vingiani et al. · 2023 · Critical Reviews in Oncology/Hematology
18. Recent Developments in the Therapeutic Landscape of Advanced or Metastatic Hormone Receptor–Positive Breast Cancer
    Eunice Yoojin Lee, Dae‐Won Lee, Kyung-Hun Lee, Seock‐Ah Im · 2023 · Cancer Research and Treatment
19. The promise of combining CDK4/6 inhibition with hormonal therapy in the first-line treatment setting for metastatic or recurrent endometrial adenocarcinoma
    Isabelle Laure Ray-Coquard, Bradley J. Monk, Domenica Lorusso, Haider Mahdi, Vivek A. Upadhyay, Regina Margaret Graul, Amreen Husain, Mansoor Raza Mirza, Brian M. Slomovitz · 2023 · International Journal of Gynecological Cancer
20. Ratios of monocytes and neutrophils to lymphocytes in the blood predict benefit of CDK4/6 inhibitor treatment in metastatic breast cancer
    Stefanos Ioannis Moukas, Sabine Kasimir‐Bauer, Mitra Tewes, Hans‐Christian Kolberg, Oliver Hoffmann, Rainer Kimmig, Corinna Keup · 2023 · Scientific Reports
21. The Clinicopathological Significance of the Cyclin D1/E1–Cyclin-Dependent Kinase (CDK2/4/6)–Retinoblastoma (RB1/pRB1) Pathway in Epithelial Ovarian Cancers
    Ayat Lashen, Mashael Algethami, Shatha Alqahtani, Ahmed Shoqafi, Amera Sheha, Jennie N. Jeyapalan, Nigel Patrick Mongan, Emad A. Rakha, Srinivasan Madhusudan · 2024 · International Journal of Molecular Sciences
22. Real-world experience with CDK4/6 inhibitors in hormone receptor-positive metastatic and recurrent breast cancer: findings from an Asian population
    Bo-Fang Chen, Yi‐Fang Tsai, Ta‐Chung Chao, Pei‐Ju Lien, Yen‐Shu Lin, Chin-Jung Feng, Yen-Jen Chen, Han-Fang Cheng, Chun‐Yu Liu, Jiun‐I Lai et al. · 2024 · Clinical and Experimental Medicine
23. Profiling the Cardiovascular Toxicities of CDK4/6 Inhibitors: A Real-World Pharmacovigilance Study
    Jae Hyun Kim · 2024 · Cancers
24. Predictors of response to CDK4/6i retrial after prior CDK4/6i failure in ER+ metastatic breast cancer
    Nicholas Mai, Carlos Henrique dos Anjos, Pedram Razavi, Anton Mikhailovich Safonov, Sujata Patil, Yuan Chen, Joshua Z. Drago, Shanu Modi, Jacqueline Bromberg, Chau T. Dang et al. · 2024 · npj Breast Cancer
25. The journey of patients affected by metastatic hormone receptor-positive/HER2-negative breast cancer from CDK 4/6 inhibitors to second-line treatment: A real-world analysis of 701 patients enrolled in the GIM14/BIOMETA study
    Chiara Molinelli, Marco Bruzzone, Eva Blondeaux, Tommaso Ruelle, Chiara Lanzavecchia, Michelino De Laurentiis, Stefania Russo, Ferdinando Riccardi, Valentina Sini, Francesco Cognetti et al. · 2024 · European Journal of Cancer
26. Real-world effectiveness of CDK4/6i in first-line treatment of HR+/HER2− advanced/metastatic breast cancer: updated systematic review
    Nadia Harbeck, Adam Brufsky, Chloe Grace Rose, Beata Korytowsky, Connie Chen, Krista Tantakoun, Endri Jazexhi, Do Hoang Vien Nguyen, Meaghan Bartlett, Imtiaz A. Samjoo et al. · 2025 · Frontiers in Oncology
27. Use of Pharmacokinetic and Pharmacodynamic Data to Develop the CDK4/6 Inhibitor Ribociclib for Patients with Advanced Breast Cancer
    Yan Ji, Hilmar Schiller, Shu Yang, Michelle Quinlan, Christelle Darstein, Felix Huth, Serge Winter, Abhijit Chakraborty · 2024 · Clinical Pharmacokinetics
28. Research highlights of clinical oncology early 2022
    Kaichun Wu · 2022 · Holistic Integrative Oncology
29. Effect of Concurrent Proton Pump Inhibitors With Palbociclib Tablets for Metastatic Breast Cancer
    Timothy J. Schieber, Samantha Steele, Stephanie Collins, Michael J. Berger, Megan Fleming, Eric M. McLaughlin, Preeti Khetarpal Sudheendra, Craig A. Vargo · 2023 · Clinical Breast Cancer
30. Long-term use of denosumab and its association with skeletal-related events and osteonecrosis of the jaw
    Pei‐An Fu, Chin‐Yao Shen, Shuen‐Ru Yang, Chun‐Hui Lee, Huiwen Chen, Edward Chia‐Cheng Lai, Wei‐Pang Chung · 2023 · Scientific Reports
31. Managing a Long and Winding Road: Estrogen Receptor–Positive Breast Cancer
    Michael Gnant, Nicholas C. Turner, Cristina Hernándo · 2023 · American Society of Clinical Oncology Educational Book
32. CDK4/6 inhibitors versus weekly paclitaxel for treatment of ER+/HER2- advanced breast cancer with impending or established visceral crisis
    Roya Behrouzi, Anne Caroline Armstrong, Sacha Jon Howell · 2023 · Breast Cancer Research and Treatment
33. Trends in HR+ metastatic breast cancer survival before and after CDK4/6 inhibitor introduction in the United States: a SEER registry analysis of patients with HER2− and HER2+ metastatic breast cancer
    Adam Brufsky, Marilyn L. Kwan, Rickard Sandin, Stella Stergiopoulos, Siddharth S. Karanth, Ashley S. Cha-Silva, Doris Makari, RK Goyal · 2024 · Breast Cancer Research and Treatment
34. Why We Do Not Recommend That Women With Breast Cancer Receive Adjuvant Treatment With a CDK4/6 Inhibitor
    Ian F. Tannock, Qamar J. Khan, Tito Fojo · 2025 · Journal of Clinical Oncology
35. PARP-inhibitors for BRCA1/2-related advanced HER2-negative breast cancer: A meta-analysis and GRADE recommendations by the Italian Association of Medical Oncology
    Federica Miglietta, Michela Cinquini, Maria Vittoria Dieci, Laura Cortesi, Carmen Criscitiello, Filippo Montemurro, Lucia Del Mastro, Alberto Zambelli, Laura Biganzoli, Alessia Levaggi et al. · 2022 · The Breast
36. Sticking to the Rules: Outcome and Success Rate of Guideline-Based Diarrhea Management in Metastatic Breast Cancer Patients Treated with Abemaciclib
    Flavia Jacobs, Elisa Agostinetto, Alessandra Solferino, Rosalba Torrisi, Giovanna Masci, Armando Santoro, Rita De Sanctis · 2023 · Journal of Clinical Medicine
37. Cancer Drugs Reimbursed with Limited Evidence on Overall Survival and Quality of Life: Do Follow-Up Studies Confirm Patient Benefits?
    Gabriella Chauca Strand, Naimi Johansson, Niklas Jakobsson, Carl Bonander, Mikael Svensson · 2023 · Clinical Drug Investigation
38. Advanced Breast Cancer Care: The Current Situation and Global Disparities
    Aruni Ghose, Susannah Jane Stanway, Bhawna Sirohi, Miriam Claire Mutebi, Sarah Adomah · 2023 · Seminars in Oncology Nursing
39. Matching-adjusted indirect comparison of PFS and OS comparing ribociclib plus letrozole versus palbociclib plus letrozole as first-line treatment of HR+/HER2− advanced breast cancer
    Komal L. Jhaveri, Joyce O’Shaughnessy, Peter Andreas Fasching, Sara M. Tolaney, Denise Aysel Yardley, Vikash Kumar Sharma, Chandroday Biswas, Astrid Thuerigen, Purnima Pathak, Hope S. Rugo · 2023 · Therapeutic Advances in Medical Oncology
40. Challenges and Opportunities in Breast Cancer Care in Low-Resourced Countries, Jordan as An Example
    Hikmat Abdel‐Razeq, Asem H. Mansour · 2024 · Cancers
41. QTc prolongation across CDK4/6 inhibitors: a systematic review and meta-analysis of randomized controlled trials
    Bruno Murad, Pedro Cotta Abrahão Reis, Alice Deberaldini Marinho, Ana Carolina Marin Comini, Débora Pinheiro Xavier, Beatriz Pessoa, Farah Raheem, Brenda J. Ernst, Lida A. Mina, Felipe Batalini · 2024 · JNCI Cancer Spectrum
42. Disparities in receipt of 1-st line CDK4/6 inhibitors with endocrine therapy for treatment of hormone receptor positive, HER2 negative metastatic breast cancer in the real-world setting
    Asal Pilehvari, Gretchen Genevieve Kimmick, Wen You, Gloribel Bonilla, Roger T. Anderson · 2024 · Breast Cancer Research
43. Real-World Outcomes of Ribociclib and Aromatase Inhibitor Use in First Line Hormone Receptor Positive, HER2-Negative Metastatic Breast Cancer
    Vanessa Wong, Richard DE BOER, Sally E. Baron-Hay, Robert Blum, Frances M. Boyle, Susan Li Ling Chua, Kerrie Clarke, Katharine Ellen Cuff, Michael Green, Elgene Lim et al. · 2022 · Clinical Breast Cancer
44. Molecular Mechanisms and Therapeutic Strategies to Overcome Resistance to Endocrine Therapy and CDK4/6 Inhibitors in Advanced ER+/HER2− Breast Cancer
    Paola Ferrari, Maria Luisa Schiavone, Cristian Scatena, Andrea Nicolini · 2025 · International Journal of Molecular Sciences
45. Association between fertility treatments and breast cancer risk in women with a family history or BRCA mutations: a systematic review and meta-analysis
    Xiaojing Liu, Jing Yue, Ruqiya Pervaiz · 2022 · Frontiers in Endocrinology
46. Social determinants of health and CDK4/6 inhibitor use and outcomes among patients with metastatic breast cancer
    Claire M. Sathe, Melissa Kate Accordino, David M. DeStephano, Mansi Shah, Jason Dennis Wright, Dawn L. Hershman · 2023 · Breast Cancer Research and Treatment
47. In Silico Mixed Ligand/Structure-Based Design of New CDK-1/PARP-1 Dual Inhibitors as Anti-Breast Cancer Agents
    Alessia Bono, Gabriele La Monica, Federica Alamia, Francesco Mingoia, Carla Gentile, Daniele Peri, Antonino Lauria, Annamaria Martorana · 2023 · International Journal of Molecular Sciences
48. Adjuvant CDK4/6 Inhibitors for Early Breast Cancer: How to Choose Wisely?
    Elisa Agostinetto, Luca Arecco, Evandro de Azambuja · 2023 · Oncology and Therapy
49. Clinicopathological Significance of Cyclin-Dependent Kinase 2 (CDK2) in Ductal Carcinoma In Situ and Early-Stage Invasive Breast Cancers
    Ayat Lashen, Shatha Alqahtani, Ahmed Shoqafi, Mashael Algethami, Jennie N. Jeyapalan, Nigel Patrick Mongan, Emad A. Rakha, Srinivasan Madhusudan · 2024 · International Journal of Molecular Sciences
50. Comparative efficacy and safety of CDK4/6 inhibitors combined with endocrine therapies for HR+/HER2-breast cancer: Systematic review and network meta-analysis
    Fei Tong, Yi Lu, Hongfang Ma, Jun Shen · 2024 · Heliyon
51. Unveiling the dissolution behavior of letrozole in fourteen pure solvents: Insights from experiments and molecular simulations
    Zidan Cao, Tangxu Sun, Xiangyang Tian · 2024 · Journal of Molecular Liquids
52. Radiosensitizing effects of CDK4/6 inhibitors in hormone receptor-positive and HER2-negative breast cancer mediated downregulation of DNA repair mechanism and NF-κB-signaling pathway
    Wen-Chi Yang, Ming‐Feng Wei, Yi‐Hsuan Lee, Chiun‐Sheng Huang, Sung‐Hsin Kuo · 2024 · Translational Oncology
53. Acquired gene alterations in patients treated with ribociclib plus endocrine therapy or endocrine therapy alone using baseline and end-of-treatment circulating tumor DNA samples in the MONALEESA-2, -3, and -7 trials
    Fabrice André, Nadia Solovieff, Fei Su, Aditya Bardia, Patrick Neven, Yoon Sim Yap, Debu Tripathy, Yen‐Shen Lu, DJ Slamon, Stephen Chia et al. · 2024 · Annals of Oncology
54. Palbociclib plus endocrine therapy versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (Young-PEARL): overall survival analysis of a randomised, open-label, phase 2 study
    Hee Kyung Ahn, Ji‐Yeon Kim, Kyung-Hun Lee, Gun Min Kim, Seok Yun Kang, Keun Seok Lee, Jee Hyun Kim, Kyong Eun Lee, Moon Hee Lee, Hee Jun Kim et al. · 2025 · The Lancet Oncology
55. Efficacy, safety, and patient-reported outcomes across young to older age groups of patients with HR+/HER2– advanced breast cancer treated with ribociclib plus endocrine therapy in the randomized MONALEESA-2, −3, and −7 trials
    Lowell L. Hart, Seock‐Ah Im, Sara M. Tolaney, Mario Campone, Timothy Pluard, Berta Sousa, Gilles Freyer, Thomas Decker, Kevin M. Kalinsky, Gary Mark Sopher et al. · 2025 · European Journal of Cancer
56. Targeting CDK2 and other novel cell cycle targets for breast cancer therapy
    Mei‐Kuang Chen, Linjie Luo, Nicole L. Massoumi, Khandan Keyomarsi · 2025 · Expert Opinion on Therapeutic Targets
57. Overall Survival With First-Line vs Second-Line CDK4/6 Inhibitor Use in Advanced Breast Cancer
    Noor Wortelboer, Annemiek van Ommen‐Nijhof, Inge R. H. M. Konings, Vincent van der Noort, Esther van den Pol, Cristina Guerrero Páez, Sandra D. Bakker, Sjoerd Hovenga, Alex L. T. Imholz, Yvonne J. L. Kamm et al. · 2026 · JAMA Oncology
58. Quality of life with ribociclib versus abemaciclib as first-line treatment of HR+/HER2− advanced breast cancer: a matching-adjusted indirect comparison
    Hope S. Rugo, Victoria Harmer, Joyce O’Shaughnessy, Komal L. Jhaveri, Sara M. Tolaney, Fátima Cardoso, Aditya Bardia, Vikalp Kumar Maheshwari, Sandeep Tripathi, Sina Haftchenary et al. · 2023 · Therapeutic Advances in Medical Oncology
59. Beyond PARP Inhibitors in Advanced Breast Cancer Patients with Germline BRCA1/2 Mutations: Focus on CDK4/6-Inhibitors and Data Review on Other Biological Therapies
    Marta Nerone, Lorenzo A. Rossi, Rosaria Condorelli, Vilma Ratti, Fabio Conforti, Antonella Palazzo, Rossella Graffeo · 2023 · Cancers
60. Vitiligo-like lesions induced by cyclin-dependent kinase 4/6 inhibitor Palbociclib: a case report and literature review
    Shan Gao, Guanjing Wei, Yanrong Hao · 2023 · Pathology & Oncology Research
61. Hematological toxicity of cyclin-dependent kinase 4/6 inhibitors in patients with breast cancer: a network meta-analysis and pharmacovigilance study
    Haiying Ding, Weiben Xu, Mengfei Dai, Shujing Li, Wenxiu Xin, Yinghui Tong, Chaoneng He, Xiufang Mi, Zha‐Jun Zhan, Luo Fang · 2024 · Expert Opinion on Drug Safety
62. Navigating the Complexities of Brain Metastases Management
    Afsaneh Amouzegar, Shannon Haig, Adriana Matutino Kahn, Hussein A. Tawbi, Joshua Jones, Sarah B. Goldberg · 2024 · American Society of Clinical Oncology Educational Book
63. Assessing the real-world effectiveness of 8 major metastatic breast cancer drugs using target trial emulation
    Alison Antoine, David Pérol, Mathieu Robain, Thomas Bachelot, Rémy Choquet, William Jacot, Béchir Ben Hadj Yahia, Thomas Grinda, Suzette Delaloge, Christine Lasset et al. · 2024 · European Journal of Cancer
64. Best of the year: Advanced breast cancer in 2023
    Ilana Miriam Schlam, Mariana Chávez‐MacGregor · 2024 · The Breast
65. Metastatic Breast Cancer: Prolonging Life in Routine Oncology Care
    Rudolf Weide, Stefan Feiten, C Wassmann, Bernhard Rendenbach, Ute Braun, Oswald Burkhard, Peter Ehscheidt, Marcus Schmidt · 2024 · Cancers
66. First-line therapy with palbociclib in patients with advanced HR+/HER2− breast cancer: The real-life study PALBOSPAIN
    Noelia Martínez-Jáñez, Meritxell Bellet, L.M. Manso Sànchez, Fernando Henao, Antonio Antón-Torres, Serafin M. Morales, Pablo Tolosa, V.L. Obadia Gil, Teresa Sampedro Gimeno, Raquel Andrés Conejero et al. · 2024 · Breast Cancer Research and Treatment
67. Visceral crisis in metastatic breast cancer: an old concept with new perspectives
    Matheus de Oliveira Andrade, Renata Colombo Bonadio, Maria Del Pilar Estevez-Diz, Laura Testa · 2024 · Clinics
68. Comparative effectiveness analysis of survival with first-line palbociclib or ribociclib plus AI in HR + /HER2- advanced breast cancer (CEPRA study): preliminary analysis of real-world data from Thailand
    Thanate Dajsakdipon, Thiti Susiriwatananont, Concord Wongkraisri, Suthinee Ithimakin, Napa Parinyanitikul, Archara Supavavej, Arunee Dechaphunkul, Patrapim Sunpaweravong, Sunee Neesanun, Charuwan Akewanlop et al. · 2024 · BMC Cancer
69. Nicotinamide Mononucleotide Alleviates Bile Acid Metabolism and Hormonal Dysregulation in Letrozole-Induced PCOS Mice
    Caifang Ren, Zhang Shuang, Jianyu Ma, Junjie Huang, Pan Huang, Mingzi Qu, Haoyue Zhao, Zhengrong Zhou, Aihua Gong · 2024 · Biology
70. Real-world comparison of palbociclib, abemaciclib, and dalpiciclib as first-line treatments for Chinese HR+/HER2−metastatic breast cancer patients: a multicenter study (YOUNGBC-28)
    Yifan Chen, Yizhao Xie, Die Sang, Ning Xie, Xinhua Han, Yanxia Zhao, Juanjuan Li, Jian Yue, Peng Yuan, Biyun Wang · 2024 · Therapeutic Advances in Medical Oncology
71. Health-Related Quality of Life in Patients with HR+/HER2− Early Breast Cancer Treated with Ribociclib Plus a Nonsteroidal Aromatase Inhibitor: Results from the NATALEE Trial
    Peter Andreas Fasching, Dennis J. Slamon, Zbigniew Ireneusz Nowecki, Bożena Kukiełka-Budny, Daniil Stroyakovskiy, Denise Aysel Yardley, Chiun‐Sheng Huang, Arlene Chan, Stephen Chia, Miguel Martín et al. · 2025 · Clinical Cancer Research
72. Pharmacogenomics for Prediction of Cardiovascular Toxicity: Landscape of Emerging Data in Breast Cancer Therapies
    Renske Altena, Svetlana Bajalica‐Lagercrantz, Andri Papakonstantinou · 2022 · Cancers
73. The likelihood of being helped or harmed as a patient-centred tool to assess cyclin dependent kinase 4/6 inhibitors clinical impact and safety in metastatic breast cancer: a systematic review and sensitivity-analysis
    Luca Mastrantoni, Armando Orlandi, Antonella Palazzo, Giovanna Garufi, Alessandra Fabi, Gennaro Daniele, Diana Giannarelli, Giampaolo Tortora, Emilio Bria · 2023 · EClinicalMedicine
74. New Developments in Systemic Management for High-Risk Early-Stage Hormone-Receptor-Positive, HER2-Negative Breast Cancer
    Jamie O. Brett, Erica L. Mayer · 2023 · Current Treatment Options in Oncology
75. Anti-hormonal maintenance treatment with the CDK4/6 inhibitor ribociclib after 1st line chemotherapy in hormone receptor positive / HER2 negative metastatic breast cancer: A phase II trial (AMICA)
    Thomas W. Decker, Kerstin Lüdtke-Heckenkamp, Luidmila Melnichuk, Nader Hirmas, Kristina Lübbe, Mark‐Oliver Zahn, Marcus Schmidt, Carsten Denkert, Ralf Lorenz, Volkmar Müller et al. · 2023 · The Breast
76. Phase II Trial of Ribociclib Plus Letrozole in Women With Recurrent Low-Grade Serous Carcinoma of the Ovary, Fallopian Tube, or Peritoneum: A GOG Partners Trial (GOG 3026)
    Brian M. Slomovitz, S. John Weroha, Wei Deng, Hye Sook Chon, Vivek Podder, Mary Tilley Jenkins Vogel, Floor Jenniskens Backes, Eric D. Thomas, Lee-may Chen, Meaghan Elizabeth Tenney et al. · 2025 · Journal of Clinical Oncology
77. CDK4/6 Inhibitors in the First-Line Treatment of Postmenopausal Women with HR+/HER2− Advanced or Metastatic Breast Cancer: An Updated Network Meta-Analysis and Cost-Effectiveness Analysis
    Ni Zeng, Jiaqi Han, Zijian Liu, Jinlan He, Kun Tian, Nianyong Chen · 2023 · Cancers
78. Intracellular spatiotemporal metabolism in connection to target engagement
    Jingwei Zhang, Zhixia Qiu, Yongjie Jessica Zhang, Guangji Wang, Haiping Hao · 2023 · Advanced Drug Delivery Reviews
79. Current Status and Future Perspectives of Antibody–Drug Conjugates in Hormone Receptor-Positive Breast Cancer
    Μaria Grammoustianou, Foteinos-Ioannis D. Dimitrakopoulos, Angelos K. Koutras · 2024 · Cancers
80. First- vs second-line CDK 4/6 inhibitor use for patients with hormone receptor positive, human epidermal growth-factor receptor-2 negative, metastatic breast cancer in the real world setting
    Gretchen Genevieve Kimmick, Asal Pilehvari, Wen You, Gloribel Bonilla, Roger T. Anderson · 2024 · Breast Cancer Research and Treatment
81. Comparative cost-effectiveness analysis of CDK4/6 inhibitors in the first-line treatment of HR-positive and HER2-negative advanced breast cancer: a Markov's model-based evaluation
    Shereen Elazzazy, Nour Hisham Al-Ziftawi, Mohamed Izham Mohamed Ibrahim, Salha Mohammed Bujassoum, Anas Ahmad Hamad · 2024 · Frontiers in Oncology
82. Development of bioengineered 3D patient derived breast cancer organoid model focusing dynamic fibroblast–stem cell reciprocity
    Nakka Sharmila Roy, Mamta Kumari, Kamare Alam, Anamitra Bhattacharya, Santanu Kaity, Kulwinder Kaur, V. Ravichandiran, Subhadeep Roy · 2024 · Progress in Biomedical Engineering
83. CXCR4 promotes tumor stemness maintenance and CDK4/6 inhibitors resistance in ER-positive breast cancer
    Qianfeng Shi, Yang Wang, Yiye Ouyang, Yujie Liu, Zijie Cai · 2025 · Breast Cancer Research
84. Adjuvant CDK4/6 inhibitors in breast cancer: Interpreting trial design, evidence, and uncertainty
    Saroj Niraula · 2025 · Cancer Treatment Reviews
85. Cost-effectiveness of ribociclib versus palbociclib in combination with an aromatase inhibitor as first-line treatment of postmenopausal women with HR+/HER2− advanced breast cancer: analysis based on final OS results of MONALEESA-2 and PALOMA-2
    David Cameron, Vikash Kumar Sharma, Chandroday Biswas, Cathy Clarke, David Chandiwana, Purnima Pathak · 2023 · Journal of Medical Economics
86. Indirect Treatment Comparison of First-Line CDK4/6-Inhibitors in Post-Menopausal Patients with HR+/HER2− Metastatic Breast Cancer
    Joseph Jonathan Zhao, Khi Yung Fong, Yiong Huak Chan, Jeremy Chee Seong Tey, Shaheenah S. Dawood, Soo Chin Lee, Richard S. Finn, Raghav Sundar, Joline S.J. Lim · 2023 · Cancers
87. Interstitial lung disease and CDK4/6 inhibitors in the treatment of breast cancer
    Ilana Miriam Schlam, Antonio Giordano, Sara M. Tolaney · 2023 · Expert Opinion on Drug Safety
88. Cyclin-Dependent Kinase 4/6 Inhibitors Plus Endocrine Therapy versus Endocrine Therapy Alone for HR-Positive, HER-2-Negative Early Breast Cancer: Meta-Analysis of Phase III Randomized Clinical Trials
    Francisco Cézar Aquino de Moraes, Gustavo de Oliveira Almeida, Vinícius Freire Costa Alves, Jonathan N. Priantti, Giovanna Da Conceição Gomes, Sarah Vitoria Bristot Carnevalli, Thiago Madeira, Maysa Vilbert, Carlos Stecca, Maria Cristina Figueroa Magalhães et al. · 2024 · Journal of Personalized Medicine
89. Intrinsic subtypes and therapeutic decision-making in hormone receptor-positive/HER2-negative metastatic breast cancer with visceral crisis: A case report
    Francesco Schettini, Elia Seguí, Benedetta Conte, Esther Sanfeliu, Blanca González‐Farré, Pedro Jares, Sergi Vidal‐Sicart, Sergi Ganau, Isaac Cebrecos, Fara Brasó‐Maristany et al. · 2022 · Frontiers in Oncology
90. A phase I trial of palbociclib and bosutinib with fulvestrant in patients with metastatic hormone receptor positive and HER2 negative (HR+ HER2-) breast cancer refractory to an aromatase inhibitor and a CDK4/6 inhibitor
    Tina Roy, Elizabeth Dominic Barrows, Candace Bavette Mainor, Julie Marie Collins, Filipa C. Lynce, Claudine J. Isaacs, Paula Raffin Pohlmann · 2023 · Contemporary Clinical Trials Communications
91. Real World Experience of Second-Line Treatment Strategies after Palbociclib and Letrozole: Overall Survival in Metastatic Hormone Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer
    Ji‐Yeon Kim, Junghoon Shin, Jin Seok Ahn, Yeon Hee Park, Young‐Hyuck Im · 2023 · Cancers
92. Implementation and evaluation of a shared care model between oncologists and pharmacists for breast cancer patients at a Canadian regional ambulatory cancer centre
    Elaine Goh, Sylvie Labelle, Angela Chan · 2023 · Journal of Oncology Pharmacy Practice
93. Fundamental Considerations of Targeted Drug Therapies for Breast Cancer
    Ileana Castillo‐Tobías, Lia Berlanga, Joan Poblano, María del Carmen Rodríguez‐Salazar, Hilda Aguayo‐Morales, Luis Enrique Cobos-Puc · 2023 · Future Pharmacology
94. Identification of a Panel of miRNAs Associated with Resistance to Palbociclib and Endocrine Therapy
    Rosalba Torrisi, Valentina Vaira, Laura Giordano, Bethania Fernandes, Giuseppe Saltalamacchia, Raffaella Palumbo, Carlo Carnaghi, Vera Basilico, Francesco Gentile, Giovanna Masci et al. · 2024 · International Journal of Molecular Sciences
95. The efficacy of palbociclib and ribociclib in the first-line treatment of metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer in male patients: a Turkish oncology group (TOG) study
    Hasan Çağrı Yıldırım, Yasin Kutlu, Emel Mutlu, Musa Barış Aykan, Mustafa Korkmaz, Selim Yalçın, Teoman Şakalar, Özde Melisa Celayir, Erkan Kayıkçıoğlu, Ferit Aslan et al. · 2024 · International Journal of Clinical Oncology
96. Efficacy of first-line CDK 4-6 inhibitors in premenopausal patients with metastatic breast cancer and the effect of dose reduction due to treatment-related neutropenia on efficacy: a Turkish Oncology Group (TOG) study
    Hasan Çağrı Yıldırım, Caner Kapar, Barış Köksal, Mustafa Seyyar, Pervin Can Sanci, Murad Guliyev, Perihan Perkin, Mustafa Büyükkör, Şendağ Yaslıkaya, Nargız Majidova et al. · 2024 · Journal of Chemotherapy
97. Cost-Effectiveness of Adjuvant Abemaciclib and Ribociclib in High-Risk Hormone Receptor–Positive Early Breast Cancer: An Indian Perspective
    Manraj Singh Sra, Archana Sasi, Atul Batra, Sameer Bakhshi, Shuvadeep Ganguly · 2024 · JCO Global Oncology
98. Beyond clinical trials: CDK4/6 inhibitor efficacy predictors and nomogram model from real‐world evidence in metastatic breast cancer
    Binliang Liu, Zheyu Hu, Ning Xie, Liping Liu, Jing Li, Xiaohong Yang, Huawu Xiao, Xu-Ran Zhao, Can Tian, Hui Min Wu et al. · 2024 · Cancer Innovation
99. Association between cyclin-dependent kinase 4/6 inhibitors and nephrotoxicity in patients with breast cancer: A Systematic Review and meta-analysis
    Jiayong Cui, Jinquan Sun, Xueying Zhou, Yi Li, Jiuda Zhao, Guoshuang Shen · 2024 · iScience
100. Efficacy of Subsequent Treatments After Disease Progression on CDK4/6 Inhibitors in Patients With Hormone Receptor–Positive Advanced Breast Cancer
     Lis Victória Ravani, Pedro Abi-Kair Borges Calomeni, Maysa Vilbert et al. · 2024 · JCO Oncology Practice